organization · Reporting owner
Column Group II GP, LP
Disclosed activity across 8 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gritstone bio, Inc.GRTS · Entity 80946 | 10% owner · General Partner | October 02, 2018 | October 02, 2018 |
| NGM BIOPHARMACEUTICALS INCNGM · Entity 11997 | 10% owner | April 05, 2024 | April 08, 2024 |
| Oric Pharmaceuticals, Inc.ORIC · Entity 4765 | 10% owner | November 12, 2021 | November 16, 2021 |
| eFFECTOR Therapeutics, Inc.EFTR · Entity 89916 | 10% owner | August 25, 2021 | September 07, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gritstone bio, Inc.
Report date October 02, 2018 · Filed October 02, 2018
Jointly reported with COLUMN GROUP II, LP, Svennilson Peter, GOEDDEL DAVID V
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,102,934 |
Reported balance
After 2018-10-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-10-02 · Conversion · Acquired 3,102,934 · Balance 3,102,934 F1: The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F2: The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3: The shares are directly held by The Column Group II, LP and indirectly held by The Column Group II GP, LP, the general partner of The Column Group II, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group II GP, LP may be deemed to have shared voting and investment power with respect to the shares. Each individual managing partner disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
| Series A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-10-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-10-02 · Conversion · Disposed 2,173,912 · Balance 0 F1: The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3: The shares are directly held by The Column Group II, LP and indirectly held by The Column Group II GP, LP, the general partner of The Column Group II, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group II GP, LP may be deemed to have shared voting and investment power with respect to the shares. Each individual managing partner disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
| Series B Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-10-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-10-02 · Conversion · Disposed 929,022 · Balance 0 F2: The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date. F3: The shares are directly held by The Column Group II, LP and indirectly held by The Column Group II GP, LP, the general partner of The Column Group II, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group II GP, LP may be deemed to have shared voting and investment power with respect to the shares. Each individual managing partner disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F2: The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.
F3: The shares are directly held by The Column Group II, LP and indirectly held by The Column Group II GP, LP, the general partner of The Column Group II, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group II GP, LP may be deemed to have shared voting and investment power with respect to the shares. Each individual managing partner disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
NGM BIOPHARMACEUTICALS INC
Report date April 05, 2024 · Filed April 08, 2024
Jointly reported with COLUMN GROUP L P, Svennilson Peter, Kutzkey Tim, Ponoi Capital II, LP, Ponoi II Management, LLC, PONOI CAPITAL, LP, Ponoi Management, LLC, COLUMN GROUP II, LP, Column Group Management LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnotes | 0 |
Reported balance
After 2024-04-05 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-04-05 · Disposition to issuer · Disposed 949,862 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3) F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2024-04-05 · Disposition to issuer · Disposed 2,650,177 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2024-04-05 · Disposition to issuer · Disposed 90,442 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2024-04-05 · Disposition to issuer · Disposed 858,035 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2024-04-05 · Disposition to issuer · Disposed 968,990 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2024-04-05 · Disposition to issuer · Disposed 2,265,758 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 8
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 8 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 9
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 9 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 10
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 10 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 11
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 11 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 12
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 12 · 2024-04-05 · Disposition to issuer · Disposed 15,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F15: The securities were owned solely by Tim Kutzkey. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-04-05 transaction · row 13
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 13 · 2024-04-05 · Disposition to issuer · Disposed 44,000 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F16: The securities were directly held by Peter Svennilson. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,000 |
Reported balance
After 2024-04-05 transaction · row 14
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 14 · 2024-04-05 · Other · Acquired 1,000 · Balance 1,000 F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-04-05 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2024-04-05 · Disposition to issuer · Disposed 11,103,333 · Balance 0 F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2) F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements. F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
Filing footnotes · ownership attribution and instrument terms
F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)
F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.
F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3)
F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F15: The securities were owned solely by Tim Kutzkey.
F16: The securities were directly held by Peter Svennilson.
F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.
Oric Pharmaceuticals, Inc.
Report date November 12, 2021 · Filed November 16, 2021
Jointly reported with COLUMN GROUP II, LP, GOEDDEL DAVID V, Svennilson Peter, Column Group LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 16,625 |
Reported balance
After 2021-11-12 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-11-12 · Exercise / conversion · Acquired 16,625 · Balance 16,625 F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 287,702 |
Reported balance
After 2021-11-16 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-11-16 · Other · Acquired 287,702 · Balance 287,702 F4: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP. F5: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-11-16 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-11-16 · Other · Disposed 287,702 · Balance 0 F6: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its partners. F5: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 86,716 |
Reported balance
After 2021-11-16 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2021-11-16 · Other · Acquired 86,716 · Balance 86,716 F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F8: These securities are directly held by David Goeddel. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 103,341 |
Reported balance
After 2021-11-16 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2021-11-16 · Other · Acquired 86,716 · Balance 103,341 F9: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 74 |
Reported balance
After 2021-11-16 transaction · row 7
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 7 · 2021-11-16 · Other · Acquired 74 · Balance 74 F10: Represents a change in the form of ownership of The Column Group, LLC ("TCG LLC") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F11: These securities are directly held by TCG LLC. The managing members of TCG LLC are the TCG II GP Managing Partners and Timothy Kutzkey (collectively, the "TCG LLC Managing Partners"). The TCG LLC Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG LLC and each of the TCG LLC Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | Direct | 3,568,181 |
Reported balance
After 2021-11-16 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-11-16 · Other · Disposed 1,200,000 · Balance 3,568,181 F2: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners. F3: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-06-15 | IndirectSee Footnote | 0 |
Reported balance
After 2021-11-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-11-12 · Exercise / conversion · Disposed 16,625 · Balance 0 F12: As of the transaction date, 16,625 of the shares subject to this option have vested. F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings. F13: The option was granted to Peter Svennilson for his service as a member of the Issuer's board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings.
F2: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners.
F3: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F4: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP.
F5: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F6: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its partners.
F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.
F8: These securities are directly held by David Goeddel.
F9: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.
F10: Represents a change in the form of ownership of The Column Group, LLC ("TCG LLC") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.
F11: These securities are directly held by TCG LLC. The managing members of TCG LLC are the TCG II GP Managing Partners and Timothy Kutzkey (collectively, the "TCG LLC Managing Partners"). The TCG LLC Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG LLC and each of the TCG LLC Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F12: As of the transaction date, 16,625 of the shares subject to this option have vested.
F13: The option was granted to Peter Svennilson for his service as a member of the Issuer's board of directors.
eFFECTOR Therapeutics, Inc.
Report date August 25, 2021 · Filed September 07, 2021
Jointly reported with Svennilson Peter, COLUMN GROUP II, LP, GOEDDEL DAVID V
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 4,309,329 |
Reported balance
Holding disclosure · report date 2021-08-25 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 4,309,329 F1: On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR" and "Issuer"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Old eFFECTOR was automatically cancelled and converted into approximately 0.09657 (the "Exchange Ratio") shares of common stock of the Issuer. F2: Represents 4,109,329 shares of the Issuer's common stock received in connection with the Merger and 200,000 shares of the Issuer's common stock that were acquired in a private placement which closed concurrently with the Merger. F3: The securities are directly held by The Column Group II, LP ("TCG II LP"). The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR" and "Issuer"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Old eFFECTOR was automatically cancelled and converted into approximately 0.09657 (the "Exchange Ratio") shares of common stock of the Issuer.
F2: Represents 4,109,329 shares of the Issuer's common stock received in connection with the Merger and 200,000 shares of the Issuer's common stock that were acquired in a private placement which closed concurrently with the Merger.
F3: The securities are directly held by The Column Group II, LP ("TCG II LP"). The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Arcus Biosciences, Inc.
Report date March 19, 2018 · Filed March 19, 2018
Jointly reported with COLUMN GROUP II, LP, Ponoi Management, LLC, PONOI CAPITAL, LP, GOEDDEL DAVID V, Svennilson Peter, Kutzkey Tim
Section 16 reporting ended · disclosed 2018-03-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,767,676 |
Reported balance
After 2018-03-19 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2018-03-19 · Conversion · Acquired 1,767,676 · Balance 1,767,676 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares |
| Common StockSEC Table I · non-derivative | Direct | 2,642,763 |
Reported balance
After 2018-03-19 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2018-03-19 · Conversion · Acquired 875,087 · Balance 2,642,763 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares |
| Common StockSEC Table I · non-derivative | Direct | 3,070,423 |
Reported balance
After 2018-03-19 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2018-03-19 · Conversion · Acquired 427,660 · Balance 3,070,423 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares |
| Common StockSEC Table I · non-derivative | Direct | 470,427 |
Reported balance
After 2018-03-19 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2018-03-19 · Conversion · Acquired 470,427 · Balance 470,427 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP") and indirectly held by Ponoi Management, LLC ("Ponoi LLC") the general partner of Ponoi LP. Ponoi LLC has voting and dispositive power with respect to these shares. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. |
| Series A Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-03-19 · Conversion · Disposed 1,767,676 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-03-19 · Conversion · Disposed 875,087 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2018-03-19 · Conversion · Disposed 427,660 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares |
| Series C Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2018-03-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2018-03-19 · Conversion · Disposed 470,427 · Balance 0 F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date. F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP") and indirectly held by Ponoi Management, LLC ("Ponoi LLC") the general partner of Ponoi LP. Ponoi LLC has voting and dispositive power with respect to these shares. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.
F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares
F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP") and indirectly held by Ponoi Management, LLC ("Ponoi LLC") the general partner of Ponoi LP. Ponoi LLC has voting and dispositive power with respect to these shares. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
IMMUNE DESIGN CORP.
Report date April 02, 2019 · Filed April 02, 2019
Jointly reported with COLUMN GROUP L P, COLUMN GROUP GP, LP, COLUMN GROUP II, LP, PONOI CAPITAL, LP, Ponoi Management, LLC, GOEDDEL DAVID V, Kutzkey Tim, Svennilson Peter
Section 16 reporting ended · disclosed 2019-04-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-04-02 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2019-04-02 · Other · Disposed 6,642,942 · Balance 0 F1: Includes shares directly held by Ponoi Capital LP ("Ponoi LP"), The Column Group II, LP ("TCG II LP") and The Column Group, LP ("TCG LP"). The Column Group II GP, LP ("TCG II GP"), as the general partner of TCG II LP, has voting and dispositive power with respect to certain of the shares. The Column Group GP, LP ("TCG GP"), as the general partner of TCG LP, has voting and dispositive power with respect to certain of the shares. Ponoi Management, LLC ("Ponoi LLC"), as the general partner of Ponoi LP, has voting and dispositive power with respect to certain of the shares. F2: (cont.) The individual managing partners of both TCG II GP and TCG GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting and dispositive power with respect to the shares owned by TCG II LP and TCG LP. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting and dispositive power with respect to the shares owned by Ponoi LP. Each individual managing partner disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes shares directly held by Ponoi Capital LP ("Ponoi LP"), The Column Group II, LP ("TCG II LP") and The Column Group, LP ("TCG LP"). The Column Group II GP, LP ("TCG II GP"), as the general partner of TCG II LP, has voting and dispositive power with respect to certain of the shares. The Column Group GP, LP ("TCG GP"), as the general partner of TCG LP, has voting and dispositive power with respect to certain of the shares. Ponoi Management, LLC ("Ponoi LLC"), as the general partner of Ponoi LP, has voting and dispositive power with respect to certain of the shares.
F2: (cont.) The individual managing partners of both TCG II GP and TCG GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting and dispositive power with respect to the shares owned by TCG II LP and TCG LP. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting and dispositive power with respect to the shares owned by Ponoi LP. Each individual managing partner disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest in such shares.
Nurix Therapeutics, Inc.
Report date May 07, 2021 · Filed May 07, 2021
Jointly reported with COLUMN GROUP L P, COLUMN GROUP GP, LP, COLUMN GROUP II, LP, PONOI CAPITAL, LP, Ponoi Management, LLC, Ponoi II Management, LLC, Ponoi Capital II, LP, Kutzkey Tim, GOEDDEL DAVID V
Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,394,333 |
Reported balance
After 2021-05-05 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-05-05 · Other · Disposed 2,000,000 · Balance 1,394,333 F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group, LP ("TCG LP") to its general and limited partners. F2: The securities are directly held by TCG LP, and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson (the "Managing Partners"). The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 438,338 |
Reported balance
After 2021-05-05 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2021-05-05 · Other · Acquired 438,338 · Balance 438,338 F3: Represents a change in the form of ownership of TCG GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F4: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,307 |
Reported balance
After 2021-05-05 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2021-05-05 · Other · Acquired 10,307 · Balance 10,307 F5: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F6: The securities are directly held by Peter Svennilson |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,307 |
Reported balance
After 2021-05-05 transaction · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · 2021-05-05 · Other · Acquired 10,307 · Balance 10,307 F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F8: The securities are directly held by David Goeddel. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 10,307 |
Reported balance
After 2021-05-05 transaction · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · 2021-05-05 · Other · Acquired 10,307 · Balance 10,307 F9: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP. F10: The securities are directly held by Tim Kutzkey. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-05-05 transaction · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · 2021-05-05 · Other · Disposed 438,338 · Balance 0 F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG GP to its general and limited partners. F4: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 116,181 |
Reported balance
After 2021-05-05 transaction · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · 2021-05-05 · Other · Acquired 105,874 · Balance 116,181 F12: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP. F6: The securities are directly held by Peter Svennilson |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 121,554 |
Reported balance
After 2021-05-05 transaction · row 8
Holding and transaction disclosures are not merged.
1 source rowRow 8 · 2021-05-05 · Other · Acquired 111,247 · Balance 121,554 F13: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP. F8: The securities are directly held by David Goeddel. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 40,654 |
Reported balance
After 2021-05-05 transaction · row 9
Holding and transaction disclosures are not merged.
1 source rowRow 9 · 2021-05-05 · Other · Acquired 30,347 · Balance 40,654 F14: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP. F10: The securities are directly held by Tim Kutzkey. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 989,000 |
Reported balance
After 2021-05-05 transaction · row 10
Holding and transaction disclosures are not merged.
1 source rowRow 10 · 2021-05-05 · Other · Disposed 1,000,000 · Balance 989,000 F15: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners. F16: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are the Managing Partners. The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 49,689 |
Reported balance
After 2021-05-05 transaction · row 11
Holding and transaction disclosures are not merged.
1 source rowRow 11 · 2021-05-05 · Other · Acquired 49,689 · Balance 49,689 F17: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP. F18: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Reported balance
After 2021-05-05 transaction · row 12
Holding and transaction disclosures are not merged.
1 source rowRow 12 · 2021-05-05 · Other · Disposed 49,689 · Balance 0 F19: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its general and limited partners. F18: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 134,010 |
Reported balance
After 2021-05-05 transaction · row 13
Holding and transaction disclosures are not merged.
1 source rowRow 13 · 2021-05-05 · Other · Acquired 17,829 · Balance 134,010 F20: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F6: The securities are directly held by Peter Svennilson |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 139,383 |
Reported balance
After 2021-05-05 transaction · row 14
Holding and transaction disclosures are not merged.
1 source rowRow 14 · 2021-05-05 · Other · Acquired 17,829 · Balance 139,383 F21: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F8: The securities are directly held by David Goeddel. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 48,406 |
Reported balance
After 2021-05-05 transaction · row 15
Holding and transaction disclosures are not merged.
1 source rowRow 15 · 2021-05-05 · Other · Acquired 7,752 · Balance 48,406 F22: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP. F10: The securities are directly held by Tim Kutzkey. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 686,274 |
Reported balance
Holding disclosure · report date 2021-05-07 · row 16
Holding and transaction disclosures are not merged.
1 source rowRow 16 · Balance 686,274 F23: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 686,274 |
Reported balance
Holding disclosure · report date 2021-05-07 · row 17
Holding and transaction disclosures are not merged.
1 source rowRow 17 · Balance 686,274 F24: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group, LP ("TCG LP") to its general and limited partners.
F2: The securities are directly held by TCG LP, and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson (the "Managing Partners"). The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
F3: Represents a change in the form of ownership of TCG GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.
F4: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F5: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.
F6: The securities are directly held by Peter Svennilson
F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.
F8: The securities are directly held by David Goeddel.
F9: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.
F10: The securities are directly held by Tim Kutzkey.
F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG GP to its general and limited partners.
F12: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.
F13: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.
F14: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.
F15: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners.
F16: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are the Managing Partners. The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
F17: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP.
F18: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F19: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its general and limited partners.
F20: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.
F21: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.
F22: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.
F23: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
F24: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.
RAPT Therapeutics, Inc.
Report date December 23, 2024 · Filed December 23, 2024
Jointly reported with COLUMN GROUP II, LP, PONOI CAPITAL, LP, Ponoi Management, LLC, Ponoi Capital II, LP, Ponoi II Management, LLC, Kutzkey Tim, GOEDDEL DAVID V, Svennilson Peter, Column Group LLC
Section 16 reporting ended · disclosed 2024-12-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,000 |
Reported balance
After 2024-12-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-12-23 · Other · Disposed 1,352,008 · Balance 50,000 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 0 |
Reported balance
After 2024-12-23 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2024-12-23 · Other · Disposed 1,599,417 · Balance 0 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,236,261 |
Reported balance
Holding disclosure · report date 2024-12-23 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,236,261 F4: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 42,189 |
Reported balance
Holding disclosure · report date 2024-12-23 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 42,189 F5: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 163 |
Reported balance
Holding disclosure · report date 2024-12-23 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 163 F6: The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 145,401 |
Reported balance
Holding disclosure · report date 2024-12-23 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 145,401 F7: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 1,352,008 |
Reported balance
After 2024-12-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-12-23 · Other · Acquired 1,352,008 · Balance 1,352,008 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
| Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee footnote | 1,599,417 |
Reported balance
After 2024-12-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-12-23 · Other · Acquired 1,599,417 · Balance 1,599,417 F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share. F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.
F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F4: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F5: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.
F6: The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F7: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.
F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 04, 2019 Filed Nov 4, 2019 17:43 UTC | RAPT Therapeutics, Inc. RAPT · Entity 62554 | ConversionCommon Stock | 2,463,659 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-054999 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP II, LP · CIK 0001600420 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Svennilson Peter · CIK 0001606074 · 10% owner · Managing Partner Column Group II Management, LP · CIK 0001783952 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,463,659 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: At the closing of the Issuer's initial public offering, each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock,and Series C-2 Preferred Stock of the Issuer automatically converted into approximately 0.166 shares of the Issuer's common stock (on an adjusted basis, after giving effect to the 1-for-6 reverse stock split of the common stock effected by the Issuer on July 19, 2019) for no additional consideration. Shares of Series B Preferred Stock have no expiration date. F2 · ownership.direct: The securities are directly held by The Column Group II, LP ("TCG II LP") and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| November 04, 2019 Filed Nov 6, 2019 17:50 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 8,409 | $11.99 | $100,823.91 |
DisclosureSEC source: 0001209191-19-055549 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,907 F1 · shares: Consists of 3,949 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 4,460 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| October 23, 2019 Filed Oct 24, 2019 19:21 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 2,087 | $11.86 | $24,751.82 |
DisclosureSEC source: 0001209191-19-053932 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,498 F4 · shares: Consists of 980 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 1,107 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| October 22, 2019 Filed Oct 24, 2019 19:21 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 2,300 | $12.00 | $27,600.00 |
DisclosureSEC source: 0001209191-19-053932 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 243,411 F1 · shares: Consists of 1,080 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 1,220 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| October 21, 2019 Filed Oct 21, 2019 19:21 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 43,400 | $11.94 | $518,196.00 |
DisclosureSEC source: 0001209191-19-053732 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,111 F5 · shares: Consists of 20,382 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 23,018 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| October 18, 2019 Filed Oct 21, 2019 19:21 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 34,721 | $11.29 | $392,000.09 |
DisclosureSEC source: 0001209191-19-053732 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,711 F4 · shares: Consists of 16,306 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 18,415 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| October 17, 2019 Filed Oct 21, 2019 19:21 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 6,818 | $10.62 | $72,407.16 |
DisclosureSEC source: 0001209191-19-053732 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,990 F1 · shares: Consists of 3,202 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 3,616 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| October 16, 2019 Filed Oct 16, 2019 20:27 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 34,900 | $10.26 | $358,074.00 |
DisclosureSEC source: 0001209191-19-053343 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,172 F1 · shares: Consists of 16,390 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 18,510 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| October 15, 2019 Filed Oct 16, 2019 20:27 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 33,200 | $10.31 | $342,292.00 |
DisclosureSEC source: 0001209191-19-053343 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,272 F4 · shares: Consists of 15,592 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 17,608 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 20:27 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 34,900 | $10.36 | $361,564.00 |
DisclosureSEC source: 0001209191-19-053343 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,072 F1 · shares: Consists of 16,390 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 18,510 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| October 11, 2019 Filed Oct 11, 2019 19:56 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 17,724 | $10.57 | $187,342.68 |
DisclosureSEC source: 0001347769-19-000017 · primary_doc.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,172 F1 · shares: Consists of 8,324 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 9,400 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| October 10, 2019 Filed Oct 11, 2019 19:56 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 17,724 | $10.50 | $186,102.00 |
DisclosureSEC source: 0001347769-19-000017 · primary_doc.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,448 F1 · shares: Consists of 8,324 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 9,400 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| October 09, 2019 Filed Oct 11, 2019 19:56 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 17,724 | $10.26 | $181,848.24 |
DisclosureSEC source: 0001347769-19-000017 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,724 F1 · shares: Consists of 8,324 shares of Common Stock held directly by The Column Group III, LP ("TCG III LP") and 9,400 shares of Common Stock held directly by The Column Group III-A, LP ("TCG III-A LP"). F2 · ownership.direct: The securities are directly held by TCG III, and indirectly held by The Column Group III GP, LP ("TCG III GP"), the general partner of TCG III. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by TCG III-A LP, and indirectly held by TCG III GP, the general partner of TCG III-A LP. The managing partners of TCG III GP are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of TCG III GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| August 09, 2019 Filed Aug 9, 2019 19:49 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 152 | $13.99 | $2,126.48 |
DisclosureSEC source: 0000899243-19-021514 · doc4.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,597,816 F5 · shares: Consists of 76 shares of Common Stock held directly by Ponoi LP and 76 shares of Common Stock held directly by Ponoi II LP. F6 · balance_after: Consists of 1,298,908 shares of Common Stock held directly by Ponoi LP and 1,298,908 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| August 08, 2019 Filed Aug 9, 2019 19:49 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 12 | $13.98 | $167.76 |
DisclosureSEC source: 0000899243-19-021514 · doc4.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,597,664 F4 · shares: Consists of 6 shares of Common Stock held directly by Ponoi LP and 6 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| August 07, 2019 Filed Aug 9, 2019 19:49 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 224,500 | $14.00 | $3,143,000.00 |
DisclosureSEC source: 0000899243-19-021514 · doc4.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,597,652 F1 · shares: Consists of 112,250 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 112,250 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| August 06, 2019 Filed Aug 7, 2019 18:37 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 310 | $13.96 | $4,327.60 |
DisclosureSEC source: 0001347769-19-000015 · primary_doc.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,373,152 F4 · shares: Consists of 155 shares of Common Stock held directly by Ponoi LP and 155 shares of Common Stock held directly by Ponoi II LP. F5 · balance_after: Consists of 1,186,576 shares of Common Stock held directly by Ponoi LP and 1,186,576 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| August 05, 2019 Filed Aug 7, 2019 18:37 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 5,824 | $13.98 | $81,399.72 |
DisclosureSEC source: 0001347769-19-000015 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,372,842 F1 · shares: Consists of 2,912 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 2,912 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 17:22 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 1,782 | $13.97 | $24,898.28 |
DisclosureSEC source: 0001347769-19-000014 · primary_doc.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,367,018 F4 · shares: Consists of 891 shares of Common Stock held directly by Ponoi LP and 891 shares of Common Stock held directly by Ponoi II LP. F5 · balance_after: Consists of 1,183,509 shares of Common Stock held directly by Ponoi LP and 1,183,509 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 17:22 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 2,600 | $13.98 | $36,345.92 |
DisclosureSEC source: 0001347769-19-000014 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,365,236 F1 · shares: Consists of 1,299 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 1,301 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| July 30, 2019 Filed Jul 31, 2019 17:42 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 8,855 | $13.91 | $123,195.19 |
DisclosureSEC source: 0001347769-19-000013 · primary_doc.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,362,636 F4 · shares: Consists of 4,428 shares of Common Stock held directly by Ponoi LP and 4,427 shares of Common Stock held directly by Ponoi II LP. F5 · balance_after: Consists of 1,181,319 shares of Common Stock held directly by Ponoi LP and 1,181,317 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| July 29, 2019 Filed Jul 31, 2019 17:42 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 19,201 | $13.58 | $260,726.54 |
DisclosureSEC source: 0001347769-19-000013 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,353,781 F1 · shares: Consists of 9,601 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 9,600 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| July 26, 2019 Filed Jul 26, 2019 18:57 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 30,059 | $13.59 | $408,634.07 |
DisclosureSEC source: 0001347769-19-000012 · primary_doc.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,334,580 F5 · shares: Consists of 15,029 shares of Common Stock held directly by Ponoi LP and 15,030 shares of Common Stock held directly by Ponoi II LP. F6 · balance_after: Consists of 1,167,290 shares of Common Stock held directly by Ponoi LP and 1,167,290 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 18:57 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 30,753 | $13.37 | $411,293.70 |
DisclosureSEC source: 0001347769-19-000012 · primary_doc.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,304,521 F4 · shares: Consists of 15,377 shares of Common Stock held directly by Ponoi LP and 15,376 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| July 24, 2019 Filed Jul 26, 2019 18:57 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 29,054 | $13.51 | $392,502.11 |
DisclosureSEC source: 0001347769-19-000012 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,273,768 F1 · shares: Consists of 14,527 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 14,527 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| July 23, 2019 Filed Jul 23, 2019 18:42 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 30,760 | $13.35 | $410,535.26 |
DisclosureSEC source: 0001347769-19-000011 · primary_doc.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,244,714 F5 · shares: Consists of 15,380 shares of Common Stock held directly by Ponoi LP and 15,380 shares of Common Stock held directly by Ponoi II LP. F6 · balance_after: Consists of 1,122,357 shares of Common Stock held directly by Ponoi LP and 1,122,357 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| July 22, 2019 Filed Jul 23, 2019 18:42 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 30,760 | $13.54 | $416,336.60 |
DisclosureSEC source: 0001347769-19-000011 · primary_doc.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,213,954 F4 · shares: Consists of 15,380 shares of Common Stock held directly by Ponoi LP and 15,380 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| July 19, 2019 Filed Jul 23, 2019 18:42 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 6,222 | $13.99 | $87,042.67 |
DisclosureSEC source: 0001347769-19-000011 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,183,194 F1 · shares: Consists of 3,111 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 3,111 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| July 16, 2019 Filed Jul 17, 2019 18:08 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 3,900 | $13.86 | $54,055.17 |
DisclosureSEC source: 0001347769-19-000010 · primary_doc.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,176,972 F4 · shares: Consists of 1,950 shares of Common Stock held directly by Ponoi LP and 1,950 shares of Common Stock held directly by Ponoi II LP. F5 · balance_after: Consists of 1,088,486 shares of Common Stock held directly by Ponoi LP and 1,088,486 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 18:08 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 16,188 | $13.69 | $221,547.35 |
DisclosureSEC source: 0001347769-19-000010 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,173,072 F1 · shares: Consists of 8,094 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 8,094 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| July 12, 2019 Filed Jul 15, 2019 19:38 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 21,014 | $13.88 | $291,764.68 |
DisclosureSEC source: 0001347769-19-000009 · primary_doc.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,156,884 F4 · shares: Consists of 10,507 shares of Common Stock held directly by Ponoi LP and 10,507 shares of Common Stock held directly by Ponoi II LP. F5 · balance_after: Consists of 1,078,442 shares of Common Stock held directly by Ponoi LP and 1,078,442 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| July 11, 2019 Filed Jul 15, 2019 19:38 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 10,870 | $13.87 | $150,751.68 |
DisclosureSEC source: 0001347769-19-000009 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,135,870 F1 · shares: Consists of 5,435 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 5,435 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| June 24, 2019 Filed Jun 26, 2019 16:28 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 12,240 | $13.78 | $168,650.06 |
DisclosureSEC source: 0001347769-19-000008 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,125,000 F1 · shares: Consists of 6,120 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 6,120 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · balance_after: Consists of 1,062,500 shares of Common Stock held directly by Ponoi LP and 1,062,500 shares of Common Stock held directly by Ponoi II LP. F3 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F4 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| June 21, 2019 Filed Jun 21, 2019 17:41 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 3,763 | $14.03 | $52,789.25 |
DisclosureSEC source: 0001347769-19-000007 · primary_doc.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,112,760 F5 · shares: Consists of 1,882 shares of Common Stock held directly by Ponoi LP and 1,881 shares of Common Stock held directly by Ponoi II LP. F6 · balance_after: Consists of 1,056,380 shares of Common Stock held directly by Ponoi LP and 1,056,380 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 17:41 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 15,400 | $13.86 | $213,385.48 |
DisclosureSEC source: 0001347769-19-000007 · primary_doc.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,108,997 F4 · shares: Consists of 7,700 shares of Common Stock held directly by Ponoi LP and 7,700 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 17:41 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 15,214 | $13.91 | $211,673.90 |
DisclosureSEC source: 0001347769-19-000007 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,093,597 F1 · shares: Consists of 7,607 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 7,607 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| June 14, 2019 Filed Jun 14, 2019 17:50 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 10,760 | $14.00 | $150,687.34 |
DisclosureSEC source: 0001347769-19-000006 · primary_doc.xml · nonDerivative · entry 3 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,078,383 F5 · shares: Consists of 5,380 shares of Common Stock held directly by Ponoi LP and 5,380 shares of Common Stock held directly by Ponoi II LP. F6 · balance_after: Consists of 1,039,191 shares of Common Stock held directly by Ponoi LP and 1,039,192 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| June 13, 2019 Filed Jun 14, 2019 17:50 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 11,500 | $14.13 | $162,507.65 |
DisclosureSEC source: 0001347769-19-000006 · primary_doc.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,067,623 F4 · shares: Consists of 5,750 shares of Common Stock held directly by Ponoi LP and 5,750 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| June 12, 2019 Filed Jun 14, 2019 17:50 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 7,500 | $14.00 | $104,988.75 |
DisclosureSEC source: 0001347769-19-000006 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,056,123 F1 · shares: Consists of 3,750 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 3,750 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| June 11, 2019 Filed Jun 11, 2019 18:29 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 10,900 | $13.83 | $150,717.57 |
DisclosureSEC source: 0001347769-19-000005 · primary_doc.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,048,623 F4 · shares: Consists of 5,450 shares of Common Stock held directly by Ponoi LP and 5,450 shares of Common Stock held directly by Ponoi II LP. F5 · balance_after: Consists of 1,024,311 shares of Common Stock held directly by Ponoi LP and 1,024,312 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 18:29 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 12,600 | $13.66 | $172,176.48 |
DisclosureSEC source: 0001347769-19-000005 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,037,723 F1 · shares: Consists of 6,300 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 6,300 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| June 06, 2019 Filed Jun 6, 2019 18:22 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 12,600 | $13.40 | $168,884.10 |
DisclosureSEC source: 0001347769-19-000004 · primary_doc.xml · nonDerivative · entry 2 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,025,123 F4 · shares: Consists of 6,300 shares of Common Stock held directly by Ponoi LP and 6,300 shares of Common Stock held directly by Ponoi II LP. F5 · balance_after: Consists of 1,012,561 shares of Common Stock held directly by Ponoi LP and 1,012,562 shares of Common Stock held directly by Ponoi II LP. F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 18:22 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 12,600 | $13.39 | $168,764.40 |
DisclosureSEC source: 0001347769-19-000004 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,012,523 F1 · shares: Consists of 6,300 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 6,300 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F3 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| May 20, 2019 Filed May 22, 2019 18:57 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 50,000 | $13.50 | $675,000.00 |
DisclosureSEC source: 0001614627-19-000001 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · Director · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,999,923 F1 · shares: Consists of 25,000 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 25,000 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · balance_after: Consists of 999,961 shares of Common Stock held directly by Ponoi LP and 999,962 shares of Common Stock held directly by Ponoi II LP. F3 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F4 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| May 15, 2019 Filed Jul 23, 2020 17:39 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $13.35 | $0.00 |
DisclosureSEC source: 0001209191-20-043529 · doc4.xml · derivative · entry 7 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner · General Partner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2020-08-18 F16 · security: Issued pursuant to the Issuer's Amended and Restated 2018 Equity Incentive Plan. F18 · derivative.expiration_date: The option expires 90 days from May 20, 2020, the date Mr. Svennilson's service as a director of the Issuer ceased. F1 · ownership.nature: The securities are directly held by Peter Svennilson, a former director of the Issuer who is a managing partner at The Column Group which invests through The Column Group II, LP ("TCG II LP"), Ponoi Capital, LP ("Ponoi LP"), Ponoi Capital II, LP ("Ponoi II LP"), The Column Group III, LP ("TCG III LP") and The Column Group III-A, LP ("TCG III-A LP," and, together with TCG II LP, Ponoi LP, Ponoi II LP and TCG III LP, the "Funds"), among other entities. Under the partnership agreements of the Funds and his agreement with The Column Group Management, LP ("TCGM LP"), Mr. Svennilson is deemed to hold the securities for the economic benefit of the Funds and TCGM LP. The Funds and their respective general partners, TCGM LP and the individual managing partners of such entities may be deemed indirect beneficial owners of the securities. Such reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 15, 2019 Filed Jul 23, 2020 17:39 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $13.35 | $0.00 |
DisclosureSEC source: 0001209191-20-043529 · doc4.xml · derivative · entry 6 COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner Column Group Management LP · CIK 0001645340 · 10% owner COLUMN GROUP III, LP · CIK 0001668159 · 10% owner COLUMN GROUP III-A, LP · CIK 0001668085 · 10% owner COLUMN GROUP III GP, LP · CIK 0001790965 · 10% owner · General Partner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2029-05-14 F16 · security: Issued pursuant to the Issuer's Amended and Restated 2018 Equity Incentive Plan. F17 · ownership.nature: The securities are directly held by David Goeddel, a director of the Issuer who is a managing partner at The Column Group which invests through the Funds, among other entities. Under the partnership agreements of the Funds and his agreement with TCGM LP, Mr. Goeddel is deemed to hold the securities for the economic benefit of the Funds and TCGM LP. The Funds and their respective general partners, TCGM LP and the individual managing partners of such entities may be deemed indirect beneficial owners of the securities. Such reporting persons disclaim beneficial ownership of the securities except to the extent of their pecuniary interest therein. Read SEC document |
| May 10, 2019 Filed May 13, 2019 16:43 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 17,923 | $13.85 | $248,233.55 |
DisclosureSEC source: 0001347769-19-000003 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,949,923 F1 · shares: Consists of 8,961 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 8,962 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · balance_after: Consists of 974,961 shares of Common Stock held directly by Ponoi LP and 974,962 shares of Common Stock held directly by Ponoi II LP. F3 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F4 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| May 07, 2019 Filed May 9, 2019 17:56 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | PurchaseCommon Stock | 57,000 | $14.10 | $803,700.00 |
DisclosureSEC source: 0001347769-19-000002 · primary_doc.xml · nonDerivative · entry 1 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,932,000 F1 · shares: Consists of 28,500 shares of Common Stock held directly by Ponoi Capital, LP ("Ponoi LP") and 28,500 shares of Common Stock held directly by Ponoi Capital II, LP ("Ponoi II LP"). F2 · balance_after: Consists of 966,000 shares of Common Stock held directly by Ponoi LP and 966,000 shares of Common Stock held directly by Ponoi II LP. F3 · ownership.direct: The securities are directly held by Ponoi LP, and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F4 · ownership.direct: The securities are directly held by Ponoi II LP, and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 17:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | ConversionSeries D Preferred Stock · Derivative | 3,400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-024269 · doc4.xml · derivative · entry 7 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,700,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every two shares of Series A preferred stock, Series B preferred stock, Series C preferred stock and Series D preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering, without payment of consideration. These shares have no expiration date. F1 · derivative.exercise_date: Every two shares of Series A preferred stock, Series B preferred stock, Series C preferred stock and Series D preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering, without payment of consideration. These shares have no expiration date. F1 · derivative.expiration_date: Every two shares of Series A preferred stock, Series B preferred stock, Series C preferred stock and Series D preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering, without payment of consideration. These shares have no expiration date. F3 · ownership.direct: The securities are directly held by TCG LP, and indirectly held by TCG GP, the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F4 · ownership.direct: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F13 · ownership.direct: Consists of 666,666 shares of Series D Preferred Stock that were convertible into 333,333 shares of Common Stock held directly by TCG LP and 2,733,334 shares of Series D Preferred Stock that were convertible into 1,366,667 shares of Common Stock held directly by TCG II LP. Read SEC document |
| April 08, 2019 Filed Apr 10, 2019 17:04 UTC | NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 | ConversionSeries C Preferred Stock · Derivative | 2,377,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-024269 · doc4.xml · derivative · entry 6 COLUMN GROUP L P · CIK 0001347769 · 10% owner COLUMN GROUP II, LP · CIK 0001600420 · 10% owner COLUMN GROUP GP, LP · CIK 0001614627 · 10% owner Column Group Management LP · CIK 0001645340 · 10% owner Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner PONOI CAPITAL, LP · CIK 0001707230 · 10% owner Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner Ponoi Capital II, LP · CIK 0001732601 · 10% owner Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,188,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every two shares of Series A preferred stock, Series B preferred stock, Series C preferred stock and Series D preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering, without payment of consideration. These shares have no expiration date. F1 · derivative.exercise_date: Every two shares of Series A preferred stock, Series B preferred stock, Series C preferred stock and Series D preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering, without payment of consideration. These shares have no expiration date. F1 · derivative.expiration_date: Every two shares of Series A preferred stock, Series B preferred stock, Series C preferred stock and Series D preferred stock automatically converted into one share of common stock in connection with the closing of the issuer's initial public offering, without payment of consideration. These shares have no expiration date. F3 · ownership.direct: The securities are directly held by TCG LP, and indirectly held by TCG GP, the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson. The managing partners of TCG GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F4 · ownership.direct: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson. The managing partners of TCG II GP may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares. F12 · ownership.direct: Consists of 2,340,000 shares of Series C Preferred Stock that were convertible into 1,170,000 shares of Common Stock held directly by TCG LP and 37,334 shares of Series C Preferred Stock that were convertible into 18,667 shares of Common Stock held directly by TCG II LP. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.